Pica Francesca, Gatti Antonio, Divizia Marco, Lazzari Marzia, Ciotti Marco, Sabato Alessandro Fabrizio, Volpi Antonio
BMC Infect Dis. 2014 Nov 1;14:556. doi: 10.1186/s12879-014-0556-6.
Recent information on epidemiology and management of post-herpetic neuralgia (PHN), a painful complication of zoster, is scarce.
This study was conducted at the Pain Clinic of the Policlinico Tor Vergata, Rome, Italy, on eighty-five immunocompetent patients with a clinical diagnosis of PHN. At enrollment (time 0, T0), the patients were interviewed by physicians to obtain demographic data and information about their zoster clinical history and underwent a blood test for VZV-DNA research. DN4 and SF-12 questionnaires were used to assess the neuropathic nature of pain and the overall health status, respectively. A one-year follow-up was planned for enrolled cases, who were visited at regular intervals of at least 3 months.
At T0 all the patients were at least 6 months from the episode of acute zoster and still presented with intense pain (mean VAS =6.7; mean DN4 = 5.7). Using antivirals within 72 hours from the rash onset was associated to a significant reduction of pain at T0 (p = 0.006 vs untreated patients). Only 2.6% of patients treated with antivirals during acute zoster but 18.6% of the untreated ones presented with neuropathic pain at T12 (p =0.007), even though the two groups were similar at T0. VZV-DNA was found in 5 out of the 50 available blood samples. At the last follow-up visit, PCS and MCS scores of the PHN patients were found to be recovered over those of the historical age-matched healthy controls. Undesirable side effects of analgesic therapies were observed in 15.3 to 28.8% of the patients.
Patients who six months after acute zoster still have significant neuropathic pain, have a high probability of suffering from chronic pain in the subsequent months/years. The initial antiviral treatment has a significant impact on the pain. Current strategies of analgesic therapy are effective to achieve relief of pain in PHN patients, but they are burdened with heavy and undesirable side effects.
关于带状疱疹后神经痛(PHN)这一带状疱疹疼痛并发症的流行病学和管理的最新信息匮乏。
本研究在意大利罗马托尔韦尔加塔综合医院疼痛诊所对85例具有免疫能力且临床诊断为PHN的患者进行。在入组时(时间0,T0),医生对患者进行访谈以获取人口统计学数据以及关于其带状疱疹临床病史的信息,并进行血液检测以研究VZV-DNA。分别使用DN4和SF-12问卷评估疼痛的神经病理性本质和总体健康状况。计划对入组病例进行为期一年的随访,至少每3个月定期访视一次。
在T0时,所有患者距急性带状疱疹发作至少已有6个月,且仍有剧烈疼痛(平均视觉模拟评分法[VAS]=6.7;平均DN4=5.7)。在皮疹发作后72小时内使用抗病毒药物与T0时疼痛显著减轻相关(与未治疗患者相比,p=0.006)。在急性带状疱疹期间接受抗病毒药物治疗的患者中,只有2.6%在T12时出现神经病理性疼痛,而未治疗患者中这一比例为18.6%(p=0.007),尽管两组在T0时相似。在50份可用血液样本中,有5份检测到VZV-DNA。在最后一次随访时,发现PHN患者的生理健康综合评分(PCS)和心理健康综合评分(MCS)高于年龄匹配的历史健康对照者。15.3%至28.8%的患者观察到镇痛治疗的不良副作用。
急性带状疱疹6个月后仍有明显神经病理性疼痛的患者,在随后数月/数年患慢性疼痛的可能性很高。初始抗病毒治疗对疼痛有显著影响。当前的镇痛治疗策略对缓解PHN患者的疼痛有效,但负担着严重且不良的副作用。